DE69412469D1 - Hydroxamsaeurederivate als metalloproteinase inhibitoren - Google Patents
Hydroxamsaeurederivate als metalloproteinase inhibitorenInfo
- Publication number
- DE69412469D1 DE69412469D1 DE69412469T DE69412469T DE69412469D1 DE 69412469 D1 DE69412469 D1 DE 69412469D1 DE 69412469 T DE69412469 T DE 69412469T DE 69412469 T DE69412469 T DE 69412469T DE 69412469 D1 DE69412469 D1 DE 69412469D1
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- group
- phenyl
- pct
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939305348A GB9305348D0 (en) | 1993-03-16 | 1993-03-16 | Hydroxamic acid derivatives as metalloproteinase inhibitors |
GB939320360A GB9320360D0 (en) | 1993-10-02 | 1993-10-02 | Hydroxamic acid derivatives as metalloproteinase inhibitors |
PCT/GB1994/000495 WO1994021625A1 (en) | 1993-03-16 | 1994-03-14 | Hydroxamic acid derivatives as metalloproteinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69412469D1 true DE69412469D1 (de) | 1998-09-17 |
DE69412469T2 DE69412469T2 (de) | 1999-02-04 |
Family
ID=26302598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69412469T Expired - Fee Related DE69412469T2 (de) | 1993-03-16 | 1994-03-14 | Hydroxamsaeurederivate als metalloproteinase inhibitoren |
Country Status (12)
Country | Link |
---|---|
US (1) | US5652262A (de) |
EP (1) | EP0689538B1 (de) |
JP (1) | JPH08508027A (de) |
AT (1) | ATE169621T1 (de) |
AU (1) | AU671724B2 (de) |
CA (1) | CA2158352A1 (de) |
DE (1) | DE69412469T2 (de) |
FI (1) | FI954351A (de) |
GB (1) | GB2290543B (de) |
NO (1) | NO953652L (de) |
NZ (1) | NZ262447A (de) |
WO (1) | WO1994021625A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9404046D0 (en) * | 1994-03-03 | 1994-04-20 | Smithkline Beecham Corp | Novel compounds |
GB9414157D0 (en) * | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Medical use |
GB9601042D0 (en) * | 1996-01-17 | 1996-03-20 | Smithkline Beecham Plc | Medical use |
GB9423914D0 (en) * | 1994-11-26 | 1995-01-11 | British Biotech Pharm | Polyether derivatives as metalloproteinase inhibitors |
US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US6017887A (en) * | 1995-01-06 | 2000-01-25 | Sibia Neurosciences, Inc. | Peptide, peptide analog and amino acid analog protease inhibitors |
GB9502858D0 (en) * | 1995-02-14 | 1995-04-05 | British Biotech Pharm | Novel use of matrix metalloproteinase inhibitors |
AU5002196A (en) * | 1995-03-28 | 1996-10-16 | Novo Nordisk A/S | Immunosuppressive agents |
GB9507799D0 (en) * | 1995-04-18 | 1995-05-31 | British Biotech Pharm | Metalloproteinase inhibitors |
US5917090A (en) * | 1995-06-30 | 1999-06-29 | British Biotech Pharmaceuticals Ltd. | Matrix metalloproteinase inhibitors |
AU2986295A (en) * | 1995-07-19 | 1997-02-18 | British Biotech Pharmaceuticals Limited | N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors |
US5665777A (en) * | 1995-11-14 | 1997-09-09 | Abbott Laboratories | Biphenyl hydroxamate inhibitors of matrix metalloproteinases |
AU711804B2 (en) | 1995-11-23 | 1999-10-21 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
GB9609702D0 (en) | 1996-05-09 | 1996-07-10 | Royal Free Hosp School Med | Anticoagulant peptides |
US6169075B1 (en) | 1996-09-10 | 2001-01-02 | British Biotech Pharmaceuticals Limited | Cytostatic agents |
US6462023B1 (en) | 1996-09-10 | 2002-10-08 | British Biotech Pharmaceuticals, Ltd. | Cytostatic agents |
GB9619631D0 (en) * | 1996-09-20 | 1996-11-06 | British Biotech Pharm | Combination therapy |
US5840974A (en) * | 1996-12-04 | 1998-11-24 | Britisch Biotech Pharmaceuticals, Ltd. | Metalloproteinase inhibitors |
JP3973748B2 (ja) * | 1998-01-14 | 2007-09-12 | 花王株式会社 | 発毛抑制剤 |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
BR0007491A (pt) * | 1999-01-13 | 2001-11-20 | Jomaa Pharmaka Gmbh | Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções |
GB9901863D0 (en) * | 1999-01-29 | 1999-03-17 | British Biotech Pharm | Antibacterial agents |
US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
CA2415954A1 (en) | 2000-07-19 | 2003-01-17 | Kazuhiro Maeda | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
WO2004073599A2 (en) * | 2003-02-18 | 2004-09-02 | Pfizer Inc. | Inhibitors of hepatitis c virus, compositions and treatments using the same |
AU2003227952A1 (en) * | 2003-05-17 | 2004-12-03 | British Biotech Pharmaceuticals Ltd | Metalloproteinase inhibitors |
CA2534352A1 (en) | 2003-08-08 | 2005-02-17 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
JP2007528409A (ja) | 2004-03-09 | 2007-10-11 | アリバ ファーマシューティカルズ, インコーポレイテッド | プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置 |
ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
GB8919251D0 (en) * | 1989-08-24 | 1989-10-04 | British Bio Technology | Compounds |
DK0489579T3 (da) * | 1990-12-03 | 1995-06-12 | Celltech Therapeutics Ltd | Peptidylderivater |
GB9102635D0 (en) * | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
JPH05125029A (ja) * | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド化合物又はその塩 |
GB9211706D0 (en) * | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
-
1994
- 1994-03-14 NZ NZ262447A patent/NZ262447A/en unknown
- 1994-03-14 DE DE69412469T patent/DE69412469T2/de not_active Expired - Fee Related
- 1994-03-14 JP JP6520761A patent/JPH08508027A/ja active Pending
- 1994-03-14 CA CA002158352A patent/CA2158352A1/en not_active Abandoned
- 1994-03-14 AT AT94909201T patent/ATE169621T1/de not_active IP Right Cessation
- 1994-03-14 GB GB9517704A patent/GB2290543B/en not_active Expired - Fee Related
- 1994-03-14 US US08/513,868 patent/US5652262A/en not_active Expired - Fee Related
- 1994-03-14 WO PCT/GB1994/000495 patent/WO1994021625A1/en active IP Right Grant
- 1994-03-14 AU AU62131/94A patent/AU671724B2/en not_active Ceased
- 1994-03-14 EP EP94909201A patent/EP0689538B1/de not_active Expired - Lifetime
-
1995
- 1995-09-15 NO NO953652A patent/NO953652L/no unknown
- 1995-09-15 FI FI954351A patent/FI954351A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
GB9517704D0 (en) | 1995-11-01 |
ATE169621T1 (de) | 1998-08-15 |
FI954351A0 (fi) | 1995-09-15 |
NO953652D0 (no) | 1995-09-15 |
EP0689538B1 (de) | 1998-08-12 |
AU6213194A (en) | 1994-10-11 |
US5652262A (en) | 1997-07-29 |
JPH08508027A (ja) | 1996-08-27 |
AU671724B2 (en) | 1996-09-05 |
WO1994021625A1 (en) | 1994-09-29 |
GB2290543B (en) | 1996-05-22 |
FI954351A (fi) | 1995-09-15 |
NO953652L (no) | 1995-09-15 |
DE69412469T2 (de) | 1999-02-04 |
GB2290543A (en) | 1996-01-03 |
CA2158352A1 (en) | 1994-09-29 |
NZ262447A (en) | 1996-07-26 |
EP0689538A1 (de) | 1996-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69412469D1 (de) | Hydroxamsaeurederivate als metalloproteinase inhibitoren | |
NO911962D0 (no) | Hydroksaminsyrebaserte kollagenaseinhibitorer. | |
KR927003624A (ko) | 화합물 | |
NZ330922A (en) | Hydroxamic acid derivatives substituted by a series of 2-pyrrolidinones, hydantoins, and pyrazolidinones for use with the treatment of diseases related to connective tissue degradation | |
ATE279391T1 (de) | Anti-imflammtorische indolderivate | |
BR9503582A (pt) | Composto composiçao farmaceutica utilizaçao e método de tratamento de um ser humano | |
ATE181055T1 (de) | Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren | |
ATE192036T1 (de) | Vorrichtung für die vaginale verabreichung von tamoxifen und dessen analogen | |
DK1295871T3 (da) | Vitamin D-derivater med et 22-oxa- eller 22-thiaatom, en C17-sidekæde substitueret med en syre-, ester- eller amid-gruppe og en 16(17)-dobbeltbinding | |
DE69723258T2 (de) | Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren | |
NO305165B1 (no) | 1-Arylcykloalkylsulfider, -sulfoksyder og -sulfoner, farmas°ytiske preparater og anvendelse derav | |
ATE99934T1 (de) | Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten. | |
EP1252890A4 (de) | Heilmittel und vorbeugende mittel für verdauungserkrankungen die diaminotrifluoromethylpyridinverbindungen enthalten | |
IL122247A0 (en) | Use of sulfamic acid derivatives acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels | |
DE69414396T2 (de) | Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten | |
IT1244696B (it) | Derivato chinolonico ad attivita' antibatterica e mucolitica | |
MX9709275A (es) | Uso de los derivados del acido sulfamico, carbamatos acil sulfonamidas o sulfonil para la manufactura de un medicamento para disminuir los niveles de lipoproteinas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |